Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study
DOI:
https://doi.org/10.2340/00015555-3846Keywords:
psoriasis, psoriatic arthritis, apremilast, obesity, retention rateAbstract
Apremilast is an oral selective phosphodiesterase-4 inhibitor developed recently for psoriasis treatment. The aim of this study is to assess the real-life outcomes of use of apremilast in patients with psoriasis in everyday clinical practice. A total of 159 adult patients (90 males) with plaque psoriasis were included in the study. Fifty of the patients (31%) had psoriatic arthritis. All patients started apremilast at the time of enrolment. There was a marked improvement in Psoriasis Area and Severity Index, body surface area and Dermatology Life Quality Index scores across the follow-up period (12 months). The improvements in these scores were also consistent when the patients were stratified according to increasing body mass index. Only 10.6% of the patients discontinued apremilast, because of no response. In conclusion, apremilast is an effective and safe treatment in patients with psoriasis, and its effect is not influenced by body mass index.
Downloads
References
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 205–212.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377–385.
Caputo V, Strafella C, Termine A, Dattola A, Mazzilli S, Lanna C, et al. Overview of the molecular determinants contributing to the expression of psoriasis and psoriatic arthritis phenotypes. J Cell Mol Med 2020; 24: 13554–13563.
Capon F. The genetic basis of psoriasis. Int J Mol Sci 2017; 18: 2526.
Chandra A, Ray A, Senapati S, Chatterjee R. Genetic and epigenetic basis of psoriasis pathogenesis. Mol Immunol 2015; 64: 313–323.
Vangipuram R, Alikhan A. Apremilast for the management of moderate to severe plaque psoriasis. Expert Rev Clin Pharmacol 2017; 10: 349–360.
Zerilli T, Ocheretyaner E. Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P T 2015; 40: 495–500.
Vujic I, Herman R, Sanlorenzo M, Posch C, Monshi B, Rappersberger K, et al. Apremilast in psoriasis – a prospective real-world study. J Eur Acad Dermatol Venereol 2018; 32: 254–259.
Gisondi P, Galvan A, Idolazzi L, Girolomoni G. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front Med (Lausanne) 2015; 2: 1.
Carrascosa JM, Bonanad C, Dauden E, Botella R, Olveira-Martín A; en nombre del Grupo de Trabajo en Inflamación Sistémica en Psoriasis. psoriasis and nonalcoholic fatty liver disease. Actas Dermosifiliogr 2017; 108: 506–514.
Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 2017; 76: 377–390.
Masson W, Lobo M, Molinero G. Psoriasis and cardiovascular risk: a comprehensive review. Adv Ther 2020; 37: 2017–2033.
Nicholas MN, Gooderham M. Psoriasis, depression, and suicidality. Skin Therapy Lett 2017; 22: 1–4.
Sendrasoa FA, Razanakoto NH, Ratovonjanahary V, Raharolahy O, Ranaivo IM, Andrianarison M, et al. Quality of life in patients with psoriasis seen in the Department of Dermatology, Antananarivo, Madagascar. Biomed Res Int 2020; 2020: 9292163.
Gisondi P, Girolomoni G. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. Drug Des Devel Ther 2016; 10: 1763–1770.
Keating GM. Apremilast: A review in psoriasis and psoriatic arthritis. Drugs 2017; 77: 459–472.
Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician 2017; 63: 278–285.
Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence 2016; 10: 2357–2367.
Seale L, Cardwell LA, Feldman SR. Adherence to biologics in patients with psoriasis. Expert Rev Clin Immunol 2018; 14: 155–161.
Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA. Adherence in the treatment of psoriasis: a systematic review. Dermatology 2011; 222: 363–374.
Fala L. Otezla (apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Health Drug Benefits 2015; 8: 105–110.
European Medicines Agency. (2015). Otezla summary of product characteristics. Available from https://www.ema.europa.eu/en/documents/product-information/otezla-eparproductinformationen.pdf.
Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal 2014; 26: 2016–2029.
Mease PJ. Apremilast: a phosphodiesterase 4 inhibitor for the treatment of psoriatic arthritis. Rheumatol Ther 2014; 1: 1–20.
Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 2015; 73: 37–49.
Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol 2015; 173: 1387–1399.
Cutolo M, Myerson GE, Fleischmann RM, Lioté F, Díaz-González F, Van den Bosch F, et al. A Phase III, Randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol 2016; 43: 1724–1734.
Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis 2016; 75: 1065–1073.
Reich K, Gooderham M, Green L, Bewley A, Zhang Z, Khanskaya I, et al. The efficacy and safety of apremilast, etanercept, and placebo, in patients with moderate to severe plaque psoriasis: 52-week results from a phase 3b, randomized, placebo controlled trial (LIBERATE) J Eur Acad Dermatol Venereol 2016; 31: 507–517.
Fink C, Schank TE, Trenkler N, Uhlmann L, Schäkel K. Quality of life, treatment satisfaction and efficacy of non-biological systemic therapies in patients with plaque psoriasis: study protocol for a prospective observational study. BMJ Open 2017; 7: e014279.
Knuckles MLF, Levi E, Soung J. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast. J Dermatolog Treat 2019; 30: 430–434.
Balato A, Campione E, Cirillo T, Malara G, Trifirò C, Bianchi L, et al. Long-term efficacy and safety of apremilast in psoriatic arthritis: focus on skin manifestations and special populations. Dermatol Ther 2020; 33: e13440.
Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med 2019; 25: 1822–1832.
Uguccioni M, Teixeira MM, Locati M, Mantovani A. Editorial: regulation of inflammation, its resolution and therapeutic targeting. Front Immunol 2017; 8: 415.
Netea MG, Balkwill F, Chonchol M, Cominelli F, Donath MY, Giamarellos-Bourboulis EJ, et al. A guiding map for inflammation. Nat Immunol 2017; 18: 826–831.
Hart FD, Huskisson EC. Non-steroidal anti-inflammatory drugs. Current status and rational therapeutic use. Drugs 1984; 27: 232–255.
Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol 2019; 10: 279.
Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis 2018; 77: 175–187.
Malara G, Trifirò C, Bartolotta A, Giofré C, D’Arrigo G, Testa A, et al. Real-world effectiveness and safety of Guselkumab for the treatment of psoriasis: a 6-month prospective study in a series of psoriatic patients. Eur Rev Med Pharmacol Sci 2021; 25: 406–412.
Gisondi P, Talamonti M, Chiricozzi A, Piaserico S, Amerio P, Balato A, et al. Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: Consensus Recommendations. Dermatol Ther (Heidelb) 2021; 11: 235–252.
Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 2014; 13: 290–314.
Kumar N, Goldminz AM, Kim N, Gottlieb AB. Phosphodiesterase 4-targeted treatments for autoimmune diseases. BMC Med 2013; 11: 96.
Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, et al. Identification of 15 new psoriasis susceptibility loci high lights the role of innate immunity. Nat Genet 2012; 44: 1341–1348.
Palfreeman AC, McNamee KE, McCann FE. New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther 2013; 7: 201–210.
Gisondi P, Farina S, Giordano M V, Girolomoni G. Usefulness of the Framingham risk score in patients with chronic psoriasis. Am J Cardiol 2010; 106: 1754–1757.
Gisondi P, Girolomoni G. Cardio-metabolic comorbidities and the approach to patients with psoriasis. Actas Dermosifiliogr 2009; 100: 14–21.
Kumar S, Han J, Li T, Qureshi A. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol 2013; 27: 1293–1298.
Davidovici BB, Sattar N, PrinzJ C, Jörg PC, Puig L, Emery P, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and comorbid conditions. J Invest Dermatol 2010; 130: 1785–1796.
Zweegers J, van den Reek JM, van de Kerkhof PC, Otero ME, Kuijpers AL, Koetsier MI, et al. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry. Br J Dermatol 2016; 175: 340–347.
Paroutoglou K, Papadavid A, Christodoulatos GS, Dalamaga M. Deciphering the association between psoriasis and obesity: current evidence and treatment considerations. Curr Obes Rep 2020; 9: 165–178.
Published
How to Cite
Issue
Section
Categories
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
